Cover Image
市場調查報告書

糖尿病的美國市場

US Diabetes Market Report: 2017 - 2022

出版商 IMARC Services Pvt. Ltd. 商品編碼 359384
出版日期 內容資訊 英文 52 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病的美國市場 US Diabetes Market Report: 2017 - 2022
出版日期: 2017年04月03日 內容資訊: 英文 52 Pages
簡介

本報告提供美國的糖尿病市場相關調查分析,現在、未來趨勢 (盛行率、人口統計、診斷、治療) 相關驗證,流行病學,市場趨勢,治療結構,競爭結構,市場預測等系統性資訊。

第1章 調查手法

第2章 摘要整理

第3章 糖尿病概要

  • 所謂糖尿病
  • 糖尿病的診斷和治療
  • 糖尿病的併發症

第4章 促進美國的糖尿病市場的主要原因

第5章 美國的糖尿病的流行病學

  • 糖尿病人口和盛行率
  • 人口和盛行率:各糖尿病類型 (第一型、第二型)
  • 人口和盛行率:各地區
  • 人口和盛行率:性別
  • 人口和盛行率:各年齡層

第6章 美國的糖尿病市場

  • 過去的市場趨勢
  • 市場預測
  • 市場明細:各市場區隔
  • 美國的口服抗糖尿病藥物市場
  • 美國的胰島素市場

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SRP00116IV

IMARC's new report "US Diabetes Market Report: 2017 - 2022" comprehensively discusses the US diabetes market. With more than 27 Million diabetes patients in the US, it represented the world's third largest diabetes patient pool in 2016. The prevailing cases of diabetes are largely due to rising obesity levels and an increasing aging population. It has been found in the report that more than half of the US population is either obese or overweight which is mainly due to their sedentary lifestyles, physical inactivities and unhealthy eating habits. Furthermore, the aging population in the US has been on the rise since the 1960's. People aged 65 years and above accounted for around 9% of the total population in 1960 while in 2016, this age group accounted for around 15% of the entire US population. Driven by rising incidences of diabetes and the fact that the US has one of the highest per capita healthcare expenditures, the US market for diabetes drugs has grown at a CAGR of around 13.3% during 2009-2016, reaching a value of US$ 32,783 Million in 2016.

The report has provided analysis of the population and prevalence rates of diabetes on the basis of type, region, gender and age group. The report finds that compared to Type-1 diabetes, Type-2 diabetes represents the more prevalent type, accounting for the majority of all diagnosed diabetes cases. Based on regions, urban areas currently consist of the majority of the diabetes patients as compared to rural areas. Based on gender, females presently account for the majority of the total diabetes patients. In terms of age groups, the age group 40-59 currently accounts for the majority of the total diabetes patients in the US followed by the age group 60-79 and 20-39.

The report has further segmented the US diabetes market according to drug types. The market currently consists of insulin and oral anti-diabetics, with insulin accounting for the majority of the total sales. For each of the two drug types, the report has also provided historical market trends, market breakup by class, key players and market outlook. On the basis of class, Long Acting Insulin represent the biggest class in the insulin market while DPP-IV inhibitors represent the biggest class in the oral anti-diabetics market.

This report provides an analytical and statistical insight into the US diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in the United States. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the US diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the US diabetes market in any form.

What we have achieved in this report:

Comprehensive situation analysis of the US diabetes epidemiology and its dynamics:

Focus of the Analysis:

  • Historical, current and future prevalence of diabetes in US
  • Historical, current and future prevalence of type-1 and type-2 diabetes in US
  • Historical, current and future prevalence of diabetes in the urban and rural regions in US
  • Historical, current and future prevalence of diabetes among males and females in US
  • Historical, current and future prevalence of diabetes among various age groups in US
  • Historical, current and future diagnosis rates for diabetes in US
  • Historical, current and future drug treatment rates for diabetes in US

Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

  • Performance of the Oral Antidiabetics market in US
  • Performance of key classes
  • Performance of key players
  • Market outlook

Comprehensive situation analysis of the US Insulin market and its dynamics:

Focus of the Analysis:

  • Performance of the Insulin market in US
  • Performance of key classes
  • Performance of key players
  • Market outlook

Table of Contents

1 Preface

2 Research Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Diabetes Disease Overview

  • 5.1 What is Diabetes?
  • 5.2 Diabetes Diagnosis and Treatment
    • 5.2.1 Diagnosis
    • 5.2.2 Treatment
  • 5.3 Diabetes Complications

6 US Diabetes Epidemiology

  • 6.1 Diabetes Population and Prevalence Rates
  • 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
  • 6.3 Population and Prevalence Rates by Region
  • 6.4 Population and Prevalence Rates by Gender
  • 6.5 Population and Prevalence Rates by Age Group

7 US Diabetes Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Market Forecast
  • 7.4 SWOT Analysis
    • 7.4.1 Strengths
    • 7.4.2 Weaknesses
    • 7.4.3 Opportunities
    • 7.4.4 Threats
  • 7.5 Value Chain Analysis
  • 7.6 Porter's Five Forces Analysis
    • 7.6.1 Overview
    • 7.6.2 Bargaining Power of Buyers
    • 7.6.3 Bargaining Power of Suppliers
    • 7.6.4 Degree of Competition
    • 7.6.5 Threat of New Entrants
    • 7.6.6 Threat of Substitutes
  • 7.7 Market Breakup by Segment
    • 7.7.1 US Oral Antidiabetics Market
      • 7.7.1.1 Historical Market Trends
      • 7.7.1.2 Market Breakup by Class
      • 7.7.1.3 Market Shares of Key Players
      • 7.7.1.4 Market Forecast
    • 7.7.2 US Insulin Market
      • 7.7.2.1 Historical Market Trends
      • 7.7.2.2 Market Breakup by Class
      • 7.7.2.3 Market Shares of Key Players
      • 7.7.2.4 Market Forecast

8 Competitive Landscape

  • 8.1 Competitive Structure
  • 8.2 Profiles of Key Players
    • 8.2.1 Merck
    • 8.2.2 Astra Zeneca
    • 8.2.3 Novo Nordisk
    • 8.2.4 Johnson and Johnson
    • 8.2.5 Others 

List of Figures

  • Figure 1: The Impact of Diabetes in the Human Body
  • Figure 2: Diabetes Complications
  • Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2016 & 2035
  • Figure 4: US: Overweight & Obese Population* (in Million), 2010, 2016 & 2022
  • Figure 5: Body Mass Index and Relative risk of Type-2 Diabetes
  • Figure 6: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in %)
  • Figure 7: US: Diabetes Prevalence By Age Groups, (in %)
  • Figure 8: US: Total Number of Diabetes Patients* (in 000), 2009-2016
  • Figure 9: US: Total Number of Diabetes Patients* Forecast (in 000), 2017-2022
  • Figure 10: US (Type1 & Type2): Total Number of Diabetes Patients* (in 000), 2009- 2016
  • Figure 11: US (Type1 & Type2): Total Number of Diabetes Patients* (in 000), 2017-2022
  • Figure 12: US (Urban & Rural): Total Number of Diabetes Patients* (in 000), 2009 -2022
  • Figure 13: US (Urban & Rural): Total Number of Diabetes Patients* (in 000), 2017 - 2022
  • Figure 14: US (Male & Female): Total Number of Diabetes Patients* (in 000), 2009 - 2016
  • Figure 15: US (Male & Female): Total Number of Diabetes Patients* (in 000), 2017 - 2022
  • Figure 16: US: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2009 - 2016
  • Figure 17: US: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2017 - 2022
  • Figure 18: US: Diabetes Drug Industry Overview
  • Figure 19: US: Diabetes Drug Market (in Million US$), 2009 - 2016
  • Figure 20: US: Diabetes Drug Market Forecast (in Million US$), 2017 - 2022
  • Figure 21: US: Diabetes Drug Market: SWOT Analysis
  • Figure 22: US: Diabetes Drug Market: Value Chain Analysis
  • Figure 23: US: Diabetes Drug Market: Porters Five Forces Analysis
  • Figure 24: US: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2009 - 2016
  • Figure 25: US: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2017 - 2022
  • Figure 26: US: Oral Antidiabetics Market: (in Million US$), 2009 - 2016
  • Figure 27: US: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2009 & 2016
  • Figure 28: US: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
  • Figure 29: US: Oral Antidiabetics Market: (in Million US$), 2017 - 2022
  • Figure 30: US: Insulin Market, (in Million US$), 2009 - 2016
  • Figure 31: US: Breakup of Insulin Market by Class (in %)
  • Figure 32: US: Insulin Market: Sales Share of Key Players (in %)
  • Figure 33: US: Insulin Market Forecast (in Million US$), 2017 - 2022

List of Tables

  • Table 1: Diagnosis of Diabetes
  • Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2016 & 2035
  • Table 3: US: Overweight & Obesity Statistics, 2010, 2016 & 2022
  • Table 4: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in Million)
  • Table 5: US: Total Prevalence & Number of Diabetes Patients*, 2009, 2016 & 2022
  • Table 6: US (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
  • Table 7: US (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
  • Table 8: US (Male & Female): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
  • Table 9: US: Total Prevalence & Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (In Millions), 2009, 2016 & 2022
  • Table 10: US: Diabetes Drug Market: Competitive Structure 
Back to Top